RecruitingPhase 3NCT06818266

Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Pediatric and Adult Patients With Sickle Cell Disease

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

130 participants

Start Date

Aug 27, 2025

Study Type

INTERVENTIONAL

Conditions

Sickle Cell Disease Acute Chest Syndrome

Summary

The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients with sickle cell disease (SCD) during acute chest syndrome (ACS).

Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo (NaCl 0.9%) and a drug called Tocilizumab (RoActemra®, 20 mg/mL). for people with acute chest syndrome and sickle cell disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTocilizumab (RoActemra®, 20 mg/mL).

One single intravenous infusion at 8 mg/kg (up to a maximum of 800 mg) for patients ≥ 30 kg and 12 mg/kg for patients \< 30 kg

DRUGPlacebo (NaCl 0.9%)

One single intravenous infusion

Locations(1)

Department of General Pediatrics and Sickle Cell Center, Necker-Enfants malades Hospital

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06818266

Related Trials

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT0643908232 locations

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT065466709 locations